Biotech Firm Acelyrin Inc. to Merge with Alumis Inc. in $320M Deal
Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...
Alumis price target lowered to $26 from $32 at Oppenheimer
Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $26 from $32 and keeps an Outperform rating on the shares. The firm says the ...
ETF Daily News4d
Alumis (ALMS) Projected to Post Quarterly Earnings on Wednesday
NASDAQ:ALMS opened at $4.82 on Tuesday. Alumis has a 1-year low of $4.74 and a 1-year high of $13.53. The company has a 50-day moving average of $7.80 and a 200 day moving average of $10.19.
Analysts Offer Insights on Materials Companies: Alumis Inc. (ALMS) and Martin Marietta Materials (MLM)
There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Alumis Inc. (ALMS – Research Report) and Martin ...
Morningstar4d
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to ...
Mena FN5d
Alumis To Present At Oppenheimer 35Th Annual Healthcare Life Sciences Conference
(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company ...